DRG Market Assessment 보고서

In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (Janssen) have been leading the U.S. psoriasis biologics market. However, the recent…

MARKET OUTLOOK The dynamics within the LABA/ICS FDC, LAMA, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g.,…

Since the approval of the first biosimilar in Europe more than a decade ago, the use of biosimilars has been increasing in that region. Likewise, the FDA approved the first biosimilar in 2015, and…

Triple-negative breast cancer (TNBC) is a patient population with high unmet need given the poor outcomes associated with current treatment options and the historic lack of targeted therapies…

Polycythemia Vera (PV) is a rare hematological malignancy estimated to affect approximately 50 thousand patients in the United States. Based on patient’s age and prior clinical history patients…

The U.S. glaucoma market has seen notable advances in the treatment of OAG following the launches of numerous innovative drugs over the past two years, including Bausch + Lomb’s Vyzulta and…

Trigeminal neuralgia (TGN) is a rare and painful disorder, usually triggered by innocuous stimuli, resulting in paroxysmal neuropathic facial pain in the regions served by the trigeminal nerve…

With more than a dozen disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS), the treatment journey for MS patients is varied and complex. To date, the MS market has…

Glomerulonephritis (GN) is a broad term covering various conditions involving injury and inflammation of the glomerulus, which plays an important role in the filtration of blood in the kidney. As…

Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is generally classified into three…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

Pfizer’s Xeljanz is the first-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United States and the first targeted oral therapy to launch for the moderate to severe UC…